Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
First reflex at symptom onset
Stop the transfusion immediately
Clamp the line at the first sign of reaction
Do not flush the existing tubing into the patient
Maintain IV access with normal saline
New tubing to keep vein open
Avoid running residual product
If progression beyond isolated skin findings, treat as anaphylaxis
Bronchospasm, stridor, or hypotension trigger
Class I recommendation for immediate epinephrine
Airway and breathing threats
Angioedema and laryngeal edema
Tongue or lip swelling
Stridor or voice change
Bronchospasm
Wheeze and chest tightness
SpO2 < 90% as failure marker
If airway compromise, early definitive airway control
Prepare for difficult airway from edema
Anesthesia or critical care to bedside
Circulation threats
Distributive shock from anaphylaxis
SBP < 90 mmHg
MAP < 65 mmHg
Tachycardia and poor perfusion
Weak pulses
Delayed capillary refill
If hypotension, aggressive crystalloid plus IM epinephrine
Normal saline bolus
Repeat epinephrine every 5 to 15 minutes
Key Concepts
Reaction timing and definition
Onset during or within 4 hours of transfusion
Anaphylaxis typically within minutes
Mediated by histamine from mast cells and basophils
Severity spectrum
Most reactions mild and cutaneous only
Severe anaphylaxis rare but life threatening
Early branching decisions
Isolated urticaria without fever favors allergic reaction
No fever or chills
No flank pain or dark urine
Fever or hemodynamic instability suggests another reaction
Hemolytic reaction until proven otherwise
Septic transfusion reaction consideration
Immediate consults and reporting
Notify the blood bank
Return the product and tubing for workup
Gram stain and culture per protocol
Serologic and clerical investigation
File a hemovigilance report
Document severity grade
Record interventions given
Specialist activation
Allergy and immunology for anaphylaxis
IgA and anti-IgA workup planning
Future transfusion strategy
Transfusion medicine for recurrent reactions
Washed or volume-reduced product planning
Premedication protocol design
History
Presentation pattern
Core cutaneous syndrome
Pruritus
Generalized itching
Onset during transfusion
Urticaria and hives
Wheals on trunk and limbs
Present in about 70% of reactions
Flushing and localized angioedema
Facial flushing
Periorbital or lip swelling
Systemic and severe features
Respiratory symptoms
Dyspnea and wheezing
Throat tightness or swelling
Cardiovascular and GI symptoms
Lightheadedness and palpitations
Abdominal cramping with nausea
Key historical elements
Temporal relationship
Time from transfusion start to symptoms
Within minutes suggests anaphylaxis
Within 4 hours fits allergic reaction
Volume of product infused before onset
Small volume in severe reactions
Note rate at time of reaction
Blood product type
Platelet transfusion as highest risk
Incidence about 302 per 100,000 units
Plasma-rich product
RBCs, plasma, and cryoprecipitate
Lower but real risk
Note specific component
Prior transfusion history
Number of prior transfusions
Cumulative sensitization
Chronic transfusion programs
Previous reactions and severity
Prior premedication used
Strongest predictor of recurrence
Risk factors and important clues
Personal risk factors
Atopic history
Asthma and allergic rhinitis
Eczema and food allergies
Known IgA deficiency
Anti-IgA antibodies risk anaphylaxis
Critical to elicit
Haptoglobin deficiency
More common in East Asian populations
Anti-haptoglobin antibodies
Family and collateral history
Familial IgA deficiency
Recurrent infections
Immunodeficiency history
Prior blood bank records
Documented reactions
Premedication protocols used
Important negatives
Absence of fever or chills
Distinguishes from FNHTR
Distinguishes from hemolytic reaction
Absence of pulmonary edema or hypoxemia
Argues against TACO
Argues against TRALI
Physical Exam
Vital signs
Stability snapshot
Temperature
Fever typically absent in allergic reaction
Fever should prompt FNHTR or hemolytic workup
Blood pressure
SBP < 90 mmHg as anaphylaxis marker
MAP < 65 mmHg as shock marker
Heart rate and oxygen saturation
Tachycardia in anaphylaxis
Desaturation with bronchospasm
Focused exam
Skin findings
Urticarial wheals
Trunk and extremity distribution
Confluent in severe cases
Angioedema
Lips, eyelids, and tongue
Maculopapular rash variant
Airway and respiratory exam
Upper airway
Stridor and oropharyngeal edema
Tongue or lip swelling
Lung exam
Wheezing and decreased air entry
Bilateral crackles suggest TACO or TRALI not allergy
Cardiovascular and abdominal exam
Perfusion
Tachycardia and weak pulses
Hypotension
Abdomen
Distension and tenderness in anaphylaxis
Absence of flank tenderness argues against hemolysis
PITFALLS
Anchoring on skin findings
Missing early airway involvement
Recheck voice and oropharynx
Serial airway assessment
Missing evolving hypotension
Repeat blood pressure
Trend perfusion markers
Misattributing fever
Fever not part of isolated allergic reaction
Reconsider FNHTR
Reconsider septic or hemolytic reaction
Jaundice or dark urine
Suggests hemolytic reaction
Send hemolysis workup
Differential Diagnosis
Other transfusion reactions
Febrile nonhemolytic transfusion reaction
Fever >= 1 C rise with chills
No urticaria
Most common transfusion reaction
ICD-10 R50.84 association
Cytokine mediated
Antipyretics for symptom control
Acute hemolytic transfusion reaction
Fever with flank or back pain
Dark urine and hypotension
DIC and sense of impending doom
Positive direct antiglobulin test
Hemoglobinemia and hemoglobinuria
ABO incompatibility emergency
Transfusion-related acute lung injury
Acute respiratory distress within 6 hours
Bilateral pulmonary infiltrates
Hypoxemia without circulatory overload
No urticaria or pruritus
Donor antileukocyte antibodies
Supportive ventilation
Transfusion-associated circulatory overload
Dyspnea and orthopnea
Pulmonary edema and hypertension
Elevated BNP
Volume-related mechanism
Diuresis responsive
Slower transfusion rate prevention
Infectious and non-transfusion mimics
Septic transfusion reaction
High fever and rigors
Hypotension
Most common with platelets
Positive product Gram stain and culture
Room temperature platelet storage
Empiric antibiotics
Transfusion-associated dyspnea
Respiratory distress not meeting other criteria
Excludes TRALI and TACO
Excludes allergic reaction
Diagnosis of exclusion
Supportive care
Reassess oxygenation
Non-transfusion-related anaphylaxis
Concurrent drug reaction
Antibiotic timing overlap
Latex exposure
Other allergen exposure
Review all medications given
Distinguish by timing
Laboratory Tests
Routine transfusion reaction workup
Clerical and compatibility check
Repeat type and crossmatch
Verify ABO compatibility
Confirm correct unit and patient
Direct antiglobulin test
Negative in allergic reactions
Positive suggests hemolytic reaction
Hemolysis screen
Visual inspection of plasma and urine
Pink or red plasma suggests hemolysis
Dark urine suggests hemoglobinuria
Free hemoglobin
Plasma and urine free hemoglobin
Negative in allergic reactions
CBC with peripheral smear
Baseline hemoglobin
Schistocytes suggest hemolysis
Targeted labs for severe reactions
Serum tryptase
Draw within 1 to 3 hours of onset
Elevation supports mast cell degranulation
Best window 15 minutes to 3 hours
Supports anaphylaxis diagnosis
No confirmatory test for mild reactions
Interpret with baseline tryptase
Immunologic deficiency workup
IgA level and anti-IgA antibodies
After anaphylaxis or recurrent severe reactions
Identifies IgA-deficient patients
Haptoglobin level
Evaluates for hemolysis
Screens for haptoglobin deficiency
Diagnostic Tests
Scoring Systems
Severity grading of transfusion reactions
Mild grade
Isolated cutaneous symptoms
Urticaria, pruritus, flushing
Moderate grade
Generalized urticaria
Mild bronchospasm responsive to treatment
Severe grade
Anaphylaxis with hypotension
Laryngeal edema or cardiovascular collapse
Anaphylaxis clinical criteria
Acute skin or mucosal involvement plus respiratory or hypotension
Rapid onset over minutes
Two or more organ systems
Hypotension after known allergen exposure
SBP < 90 mmHg
Drop > 30% from baseline
Limitations
No validated transfusion-specific score
Clinical trajectory supersedes grading
Severity may evolve quickly
MRI
MRI role
Not indicated acutely
No role in mild reactions
Time and availability constraints
Rare problem-solving use
Characterize airway soft tissue if needed
Only after stabilization
Contraindications
Unstable patient
Non-compatible implants
CT
CT chest indications
Respiratory distress not responding to treatment
Differentiate TRALI from TACO
Evaluate for alternative pathology
CT neck for airway compromise
Persistent edema concern
Only when airway secured or stable
Contrast considerations
Renal function assessment
Estimated GFR review
Hydration status
Allergy precautions
Prior contrast reaction history
Premedication if indicated
Ultrasound
Lung ultrasound
B-line assessment
Bilateral B-lines suggest TACO or TRALI
Helps exclude allergic-only reaction
Pleural effusion screen
Free fluid identification
Operator dependent limitation
Cardiac POCUS
Shock differential support
LV function gross estimate
Hyperdynamic in distributive shock
Volume status adjunct
IVC collapsibility in anaphylaxis
Integrate with clinical exam
Disposition
Level of care selection
Discharge candidates
Mild cutaneous reaction resolved with antihistamine
Stable vitals for >= 30 minutes
No respiratory symptoms
Reliable patient and follow-up
Educated on future precautions
Documentation of reaction provided
Observation and admission
Moderate reactions with systemic features
Observe minimum 4 to 6 hours
Any respiratory symptom even if resolved
Recurrent reactions in same episode
Extended monitoring
Reassess for alternative reaction
ICU indications
Anaphylaxis requiring epinephrine
Hemodynamic instability
Airway compromise
Biphasic anaphylaxis concern
Observe 6 to 12 hours minimum
Continuous monitoring
Consultation and follow-up
Specialist triggers
Anaphylaxis to allergy and transfusion medicine
IgA workup
Future product planning
Recurrent reactions to transfusion medicine
Washed product planning
Premedication protocol
Documentation and reporting
Hemovigilance report filed
Severity grade recorded
Blood bank notified
Reaction documented in record
Future transfusion alert
Patient-held documentation
Treatment
Immediate management for all reactions
First actions
Stop or pause the transfusion
Pause for mild cutaneous reactions
Stop permanently if beyond skin
Maintain IV access with normal saline
New tubing
Keep vein open
Assess ABCs and vital signs
Continuous monitoring
Reassess frequently
Mild allergic reaction
Antihistamine therapy
Diphenhydramine
25 to 50 mg IV or PO
Grade 1A recommendation
Monitoring response
Observe for symptom resolution
Watch for progression
Restart decision
If symptoms resolve completely
Restart same unit at slower rate
Direct observation
If symptoms recur or progress
Discontinue permanently
Treat as escalating reaction
Anaphylaxis
First-line epinephrine
Epinephrine IM 1:1000
0.3 to 0.5 mg into anterolateral thigh
Repeat every 5 to 15 minutes as needed
Refractory hypotension
Epinephrine infusion
Titrate to MAP >= 65 mmHg
Do not restart the transfusion
Permanent discontinuation
Grade 1A recommendation
Adjunctive resuscitation
Aggressive IV fluids
Normal saline bolus
Repeat per perfusion response
Oxygen and airway management
Supplemental oxygen
Prepare for difficult airway from edema
Second-line agents
H1 antihistamine
Diphenhydramine 50 mg IV
Symptom control adjunct
H2 antihistamine
Famotidine 20 mg IV
Combined H1 and H2 blockade
Bronchodilator
Albuterol nebulized for bronchospasm
Repeat as needed
Corticosteroid
Methylprednisolone 125 mg IV
Hydrocortisone 200 mg IV alternative
Prevention and premedication
Routine premedication caution
No benefit in unselected patients
RR 1.37 for allergic reactions
Acetaminophen and antihistamine ineffective broadly
Benefit only in prior severe reaction
Antihistamines plus antiallergy medications
Fewer reactions in that subgroup
Product modification
Washed blood products
Plasma protein and allergen removal
Grade 1C recommendation
Platelets in additive solution
Reduced plasma content
Alternative to washing
IgA-deficient products
For confirmed IgA deficiency with anti-IgA
Coordinate with blood bank
Refractory cases
Omalizumab
Reported for refractory platelet-induced anaphylaxis
Case-report level evidence
Special Populations
Pregnancy
Pregnancy considerations
Epinephrine remains first-line for anaphylaxis
Maternal hypoxia harms fetus
Do not withhold for pregnancy
Antihistamine selection
Diphenhydramine acceptable
Avoid unnecessary sedation
Maternal and fetal monitoring
Maintain SpO2 >= 95%
Fetal monitoring when viable gestation
Positioning
Left lateral tilt to improve venous return
Avoid supine hypotension
Geriatric
Older adult features
Higher cumulative transfusion exposure
Chronic anemia and malignancy
Repeated sensitization
Cardiovascular caution with epinephrine
Monitor for ischemia and arrhythmia
Still indicated for true anaphylaxis
Comorbidity overlap
TACO risk higher with cardiac disease
Distinguish dyspnea cause carefully
Anticholinergic sensitivity
Antihistamine-related delirium risk
Lower dosing consideration
Pediatrics
Pediatric differences
Weight-based epinephrine
0.01 mg/kg IM 1:1000
Maximum 0.3 mg per dose
Weight-based antihistamine
Diphenhydramine 1 mg/kg IV
Maximum 50 mg per dose
Higher reaction surveillance
Allergic reactions common in pediatric transfusion
Platelet products highest risk
Volume-conscious resuscitation
20 ml/kg crystalloid bolus
Reassess after each bolus
Background
Epidemiology
Incidence and burden
Among most common transfusion reactions
Platelet incidence about 302 per 100,000 units
Highest risk product
Severe anaphylaxis rate
About 8 per 100,000 units
Life-threatening potential
Presentation distribution
About 70% present with urticaria
Most reactions mild and cutaneous
High-risk populations
Chronic transfusion recipients
Sickle cell disease and thalassemia
MDS and hematologic malignancy
Prior allergic reaction
Strongest predictor of recurrence
Risk rises with each reaction
Pathophysiology
Immune mechanism
Type I hypersensitivity
Histamine release from mast cells and basophils
IgE-mediated in many cases
Recipient antibodies to donor proteins
Anti-IgA in IgA-deficient patients
Anti-haptoglobin in haptoglobin deficiency
Contributing factors
Plasma allergen load
Higher in platelet and plasma products
Donor food allergens implicated rarely
Storage-related mediators
Histamine accumulation with storage duration
Bioactive lipid accumulation
Leukoreduction effect
Non-leukoreduced products higher mediator content
Cytokine contribution
Therapeutic Considerations
Treatment principles
Epinephrine is the priority in anaphylaxis
Antihistamines and steroids are adjuncts
Steroids do not treat acute airway or shock
Restart only mild resolved cutaneous reactions
Slower rate and observation
Never restart after systemic features
Prevention strategy
Premedication targeted not routine
Reserve for prior severe reactions
Avoid masking early reaction signs
Product modification for recurrence
Washed products
Additive-solution platelets
Investigation and reporting
Blood bank workup mandatory
Rule out hemolysis and sepsis
Serologic evaluation
Hemovigilance participation
System-level safety tracking
Future transfusion planning
Patient Discharge Instructions
copy discharge instructions
Allergic transfusion reaction home care
Take antihistamines as prescribed
Diphenhydramine may cause drowsiness
Avoid driving if drowsy
Rest and stay hydrated
Resume normal activity as tolerated
Skin itching may persist briefly
Warning signs to return to ER
Trouble breathing or wheezing
Throat tightness or swelling
Blue lips or face
Dizziness or fainting
Spreading hives
Chest pain
Fever or chills
Dark urine
Flank or back pain
Future transfusion safety
Carry documentation of this reaction
Reaction type and severity
Share with future providers
Tell every provider before transfusion
Premedication may be needed
Washed products may be needed
Follow-up
Allergy and immunology after severe reaction
IgA and anti-IgA testing in 2 to 4 weeks
Tryptase and haptoglobin testing
Epinephrine auto-injector if ongoing transfusion needs
Carry at all times
Review correct use
References
Guidelines and key sources
Guideline and review sources
Delaney et al transfusion reactions review
Lancet 2016
Prevention, diagnosis, and treatment
Hirayama allergic transfusion reaction review
British Journal of Haematology 2013
Pathogenesis and prevention
Cochrane premedication review
Marti-Carvajal et al 2010
Allergic and febrile reaction prevention
Evidence summaries
Ning et al premedication meta-analysis
Transfusion 2019
No benefit in unselected patients
Wappler-Guzzetta et al severe reaction prevention
American Journal of Clinical Pathology 2025
History-guided prevention
Coding standards
ICD-10 T80.61 anaphylactic reaction due to transfusion
T80.62 other serum reaction due to transfusion
SNOMED CT allergic transfusion reaction concept
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.